The family of receptors that activate G-protein-coupled signal transduction pathways share characteristic structural features that presumably reflect their common mechanism of action (see ref 1 for review). In recent years, the deduced amino acid sequences of a large number (250) of G-proteincoupled receptors (GPCRs)2 have been elucidated. This explosion of primary sequence information is due, in large part, to the widespread application of molecular cloning techniques.
The current challenge in the field is to apply and extend this molecular information to better understand the mechanism of action of these receptors and their downstream signaling events.
GPCRs bind a variety of ligands ranging from small biogenic amines to peptides, small proteins, and large glycoprotein hormones (2) . Despite the wide range of ligands that activate these receptors, the receptors themselves share a surprising amount of structural homology, both primary and tertiary. The overall structural features of the GPCR family are highly conserved:
all of these receptors contain seven hydrophobic domains, postulated to span the plasma membrane, connected by hydrophilic extracellular and intracellular ioops. The structure-function relationships between ligand binding to the receptor and signal transduction to G-proteins have been extensively studied for several members of this family. The secretin/VIP and mGlu families share little primary sequence homology with each other or with the rhodopsin/f-adrenergic family of receptors, a!-though their overall predicted tertiary structure is similar. These receptors will be discussed at the end of this article.
MOLECULAR MODELING OF RECEPTORS
Because of the paucity of tertiary structural information on the family of GPCRs, investigators are combining biochemical, pharmacological, and genetic approaches with molecular modeling and biophysical analysis to identify key elements in the signaling mechanism of these receptors.
Unfortunately, obtaining high-quality crystals for structural determination on membrane proteins remains extremely difficult. Until the structure of at least one GPCR is determined at atomic resolution, the structural insights inferred from mutagenesis studies can be combined with computer modeling to reconcile the various experimental data and suggest further experiments to refine or support the original model. For GPCRs, one major feature in the primary sequence is the occurrence of seven relatively hydrophobic REVIEW regions, and the periodic distribution of hydrophobicity is consistent with an a-helical conformation (3) . This feature provides a rationale for modeling GPCRs after bacteriorhodopsin, which contains seven transmembrane helices and whose structure has been elucidated by electron diffraction (4 
SMALL MOLECULE BINDING SITE
The fAR, which binds the endogenous catecholamine agonists epinephrine and norepinephrine and activates the C-protein Gs to stimulate adenylyl cyclase, was the second GPCR to be cloned: after rhodopsin.
The homology of this receptor with rhodopsin that was noted at the time was the first indication that these proteins form a structurally, as well as functionally, related family of receptors (8 In fact, both agonists and antagonists interact with the side chain of Aspi 13 in the receptor (12) .
In contrast, agonist activation of the AR was determined to involve an interaction of the catechol ring of the agonist with residues in transmembrane helices 5 and 6 (13) . The aromatic catechol-containing aromatic ring appears to interact with the side chain of Phe290 in transmembrane helix 6, whereas the catechol hydroxyl groups of the agonist form hydrogen bonds with the side chains of two Ser residues, at positions 204 and 207 in transmembrane helix 5. The specific interactions between the ligand and the receptors at these positions were elucidated using 2-dimensional mutagensis, in which the activation of these mutant receptors by analogs of isoproterenol having each of the hydroxyl groups replaced with a hydrogen were analyzed. These studies indicated that there is a specific hydrogen bond linking the side chain of Ser204 to the meta-hydroxyl group of the ligand and a second specific hydrogen bond linking Ser207 in the receptor to the para-hydroxyl group of the agonist (13 A Phe residue is conserved at the position analogous to Phe290 of the fAR in the sixth transmemhrane helix of all other GPCRs that bind aromatic biogenic amine ligands, but not in the muscarinic receptors, for which the endogenous agonist is an acetylated aliphatic amine. In the muscarinic receptor family, this Phe is substituted by a Tyr residue.
Replacement of this TyrSO6 residue in the m3 muscarinic receptor with a Phe residue resulted in a decrease in the affinity of the receptor for the agonists acetylcholine and carbamylcholine with no effect on antagonist binding (18). Although the nature of the interaction between the agonists and Tyr506 has not yet been explored, these data would be consistent with an interaction between the hydroxyl group of Tyr507 and a hydrogen bond donor or acceptor on the ligand, most likely a portion of the ester moiety.
In addition, Ser residues analogous to Ser204 and 5er207 are located in helix 5 of other receptors that bind catecholamines (ai-, a2-, -dopamine), and 5er204
(but not 5er207) is conserved among the serotonin receptor family, which binds mono-hydroxytryptamine as its agonist. These correlations strongly suggest that the helix 5-6 region evolved specifically to bind the polar aromatic portion of the biogenic amine in this subfamily of GPCRs. In the muscarinic receptor family, a Thr residue is located at the position analogous to Ser204 in the AR, and 5er207 is replaced by an Ala. Substitution of this Thr234 residue in the m3 muscarinic receptor with an Ala resulted in a decrease in the affinity of the receptor for agonists but not antagonists, again suggestive of a hydrogen bonding interaction between the hydroxyl side chain of Thr234 and a functional group on the agonist (18). In the histamine receptor, these two Ser residues are replaced by Asp and Thr, respectively. Substitution of these residues independently or together resulted in a decrease in the affinity and efficacy of the interaction of the receptor with agonists (16). Taken together, these data suggest that the binding triad of the two Ser residues in transmembrane helix 5 and the Phe in transmembrane helix 6 that interact with the catechol ring of 13-adenergic agonists are representative of a similar binding pocket that is critical for the binding and agonist activation of all biogenic amine receptors, with the specificity of agonist recognition determined by the chemical nature of the side chains at these three positions.
Now that -40 different biogenic amine GPCRs have been cloned, it is possible to determine, by simple inspection of the primary sequence of a GPCR, whether the natural ligand for that receptor is a biogenic amine. The presence of an Asp at the position analogous to 113 in transmembrane helix 3, along with the pattern of residues in helices 5 and 6 described above, is diagnostic of a biogenie amine receptor (Fig. 1) , and can be used to identify such a receptor from a group of orphan receptors whose ligands are not known. In fact, such a strategy was instrumental in identification of the histamine receptor from the cloned cDNA (19) and of the orphan RDC4 as a receptor for the biogenic amine serotonin (20, 21).
PEPTIDE BINDING SITE
The endogenous ligands for many GPCRs are peptides, ranging from 3 to 40 amino acid residues in length. The design of small molecule ligands to activate or inhibit these peptidergic receptors remains a challenge for modern drug discovery.
Understanding the interaction between small peptides and their receptors is critical for establishing the link between small molecule binding and peptide binding. In addition, such studies will provide a model that may be extended to the larger peptides and proteins that also serve as ligands for GPCRs. Mapping of peptide-receptor interactions has relied heavily on the development of structure-activity relationships for substituted peptide analogs and (23) . Three residues in the first extracellular segment and at least three residues in the second extracellular segment are specifically required for the binding of substance P and related peptides.
In contrast, nonpeptide antagonist binding is not affected by amino acid substitutions or deletions at those positions (23) (24) (25) .
These data suggest that residues in the first and second extracellular segments of the NK1 receptor either interact directly with peptide agonists or play a critical role in maintaining the local conformation of the peptide binding site. The thrombin receptor presents a unique role for the NH2 terminus of a class of GPCRs that are activated by proteases. This receptor is activated by thrombin-mediated cleavage of the NH2 terminus of the receptor; the newly generated NH2 terminus then serves as a tethered ligand to activate the receptor (Liu, 1991) . The specificity of the receptor for the tethered ligand is determined by the extracellular loop regions, whereas the protease specificity is determined by the sequence in the NH2-terminal cleavage site (33, 34) .
to the NK1 receptor. Two-dimensional mutagenesis analysis suggests that the COOH terminus of substance P binds at or near Asn85 in helix 2 of the receptor, based on a comparison of the binding of the wild-type and N85A mutant receptors to the amidated peptide substance P and its methyl ester analog (36) . Residues within the transmembrane regions of other GPCRs have also been shown to be important for the binding of peptide ligands to these receptors.
Several residues in the transmembrane domain of the receptor for the tripeptide thyrotropin-releasing hormone (TRH) have been determined to be critical for the binding of the peptide (37, 38) . Two-dimensional mutagenesis experiments involving the binding of analogs of TRH to mutant TRH receptors suggest that the NH2-terminal pyroglutamate residue of TRH binds to a pocket between TyrlO#{243} and Asni 10 in transmembrane helix 3 of the receptor.
The ring carbonyl moiety of the pyroglutamate appears to interact with the hydroxyl side chain of Tyr106 on the receptor (37), with the ring nitrogen of the pyroglutamate interacting with the side chain of AsnilO (38) . This region of the TRH receptor is located in a position similar to that of the Asp residue that interacts with the amine moiety of the biogenic amine ligands in that class of receptors.
This region of transmembrane helix 3 has been shown to play a role in the binding of larger peptides to other GPCRs, as well. In the endothelin receptor family, a Lys residue is located at the position analogous to that of Aspi 13 in the 3AR. Substitution of this Lys with Asp decreased the affinity of the receptor for endothelin peptides, demonstrating a role for this residue in the interaction between the peptide agonists and the receptor (39) . In addition, Tyri29 in transmembrane helix 2 of the endothelin receptor has been determined to be critical for the potency and specificity of peptide agonists and antagonists, although the specific in- (Fig. 2) . Specifically, the benzhydryl moiety of the antagonist appears to interact with Hisi97 in transmembrane helix 5 through an amino-aromatic interaction (47) . A second interaction of this substituent with Tyr272 in transmembrane helix 6 has also recently been proposed (48) . The C3 heteroatom of the antagonist appears to form a hydrogen bond with the side chain of G1n165 in transmembrane helix 4 (49), whereas the substituted benzyl moiety of these antagonists interacts with His265 in helix 6 (50). The identification of four residues in three different transmembrane helices involved in direct interaction with quinuclidine
antagonists allows the refinement of receptor models that can be used as a framework to facilitate the design of new antagonists.
At least two other structural classes of NK1 antagonists also bind to the region defined by transmembrane helices 4-7, making slightly different sets of contacts with these key residues in the receptor. In interactions with the perhydroisoindole antagonist RP67580, Ser169, His197, His265, and Tyr287 are the most important residues identified to date (36, 49) . For the tryptophan ester antagonist L-732,138, His197, and His265 provide critical points of interaction with the receptor (51). His197 and His265 are located in approximately the same position, at the top of helices 5 and 6, in the NK1 receptor as are Ser204 and Phe290 in the 3AR.
The transmembrane domain of the AT1 angiotensin receptor has also been identified as the key site of interaction of the nonpeptide antagonists typified by the imidazolebiphenytetrazole losartan and related analogs (52, 53) . Several residues within helices 3-7 were identified as critical for the binding of small molecule antagonists to this receptor, although the specific interactions with functional groups on the ligand remain to be defined. Several of these key residues for the binding of AT1 antagonists are in positions similar to those residues determined to be critical for the binding of small molecule ligands to the I3AR and NK1 receptors.
The fact that many small molecules bind to the transmembrane region, which is the region of highest homology among the family of GPCRs, may explain the occurrence of spurious cross-reactivity of compounds among receptors whose natural ligands are not related (54) . For example, the 2-substituted benzodiazepine tifluadom is an opiate agonist and a CCK antagonist (55 Because only a few residues of the NK1 receptor are required for the binding of both agonists and antagonists, this observation implies that competitive antagonism arises primarily from a steric exclusion or allosteric effect rather than from competing interactions at the atomic level. Although an agonist bound to the receptor may not be positioned to interact directly with a residue that interacts with an antagonist, the presence of a bound agonist on the receptor is able to exclude the binding of antagonists, and vice versa. One residue, Asn295 in transmembrane helix 7, in the AT1 angiotensin receptor has been shown to interact differently with competitive and insurmountable antagonists of the losartan class (53), suggesting that key molecular interactions responsible for these different pharmacological profiles may be identified in the future.
It is obvious that the potential exists for a continuous spectrum of relationships between an agonist/antagonist pair, ranging from complete structural overlap to complete allosteric exclusion.
Based on mutational analysis of the NK1 receptor, the currently known antagonists all appear to share only a minimal number of receptor contacts with peptide agonists, such that the antagonist binding site is intercalated among helices 4-7, whereas the agonist binding site involves the extracellular domain and helices 2 and 7. This observation raises the possibility of developing new structural classes of NK1 antagonists that would bind to the "peptide site" region surrounded by helices 1, 2, and 7. In the case of CCK-B receptor, dipeptoid antagonists have been developed based on the minimal side chain elements of CCK (56) . Whether these rationally designed antagonists actually bind to the region in the receptor that would be occupied by CCK itself could be determined by mutagenesis experiments.
OTHER FAMILIES OF GPCR
The secretin/VIP family includes receptors for the peptides secretin, glucagon, glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide, parathyroid hormone, VIP, pituitary adenlylate cyclase activating polypeptide (PACAP), calcitonin, and growth hormone releasing hormone. These receptors share 25-50% amino acid identity among themselves and little primary sequence homology with the rhodopsin/3-adrenergic receptor family. Given this minimal level of sequence homology and the difficulty in isolating purified receptor from native tissues, it is not surprising that the initial cDNA clones identified in this family were discovered by expression cloning strategies (57) (58) (59) Further studies will be needed to refine the regions involved in ligand binding and to determine whether these observations apply to other members of this receptor subfamily.
All members of the secretin/VIP subfamily of receptors cloned to date are coupled to the G-protein G8, and upon activation lead to increases in levels of intracellular cAMP (57) (58) (59) .
In addition to coupling to C, many of these receptors (PTH, glucagon, GLP-i, calcitonin, PACAP) have been reported to activate other C-proteins, leading to increases in intracellular calcium levels and inositol phosphate hydrolysis (61, 62) . Thus, it appears that the potential to signal through multiple second-messenger pathways may be a hallmark of this receptor subfamily.
Mutagensis studies have implicated regions in the second and third intracellular loops or the COOH-terminal tail of the rhodopsin/3-adrenergic subfamily of GPCRs in the interaction with C-proteins (2). In the secretin/VIP family, mutagenesis revealed that removal of the COOH-terminal tail of the P1'H receptor does not alter its ability to activate adenylyl cyclase (58) . In addition, a series of PACAP receptors that have altered amino acid sequences in third intracellular loop arising from alternative spicing display differences in their selectivity for various C-proteins (62 about the environment of the fluorophore or serve as a tool to monitor the kinetics of ligand binding, they can also serve to introduce a chromophore for proximity studies using fluorescence energy transfer. Used in conjunction with labeled receptors or C-proteins, such probes could be used to address the topology of the receptor and perhaps address details of how the receptor interacts with C-proteins.
Labeling of C-protein subunits has been reported (70) and has provided information on the arrangement of the C-protein subunits (71).
Specific labeling of the receptor will best be accomplished by using site-directed mutagensis to introduce cysteines or other readily derivatized functional groups at the desired locations.
Extrinsic labeled receptor could also be used to monitor conformational changes. Such experiments using spin label probes have been performed on rhodopsin and revealed a conformational change in the loop connecting transmembrane helices 3 and 4 associated with activation of the protein (72). Fluorescence and ESR studies should be useful for determining overall receptor topology, conformational changes, and provide some information on the nature of the ligand binding site. A detailed analysis of the ligand binding site will await X-ray diffraction studies. Crystallization and X-ray diffraction studies on CPCRs will require high-level expression systems and large-scale purification. Examples of successfully crystallized membrane bound proteins are rare. However, because of the widespread therapeutic importance of GPCRs, these problems are being tackled from a variety of approaches, and crystallography of CPCRs remains a central goal in the field.
CONCLUSION
In summary, the family of GPCRs is functionally diverse and responds to a wide variety of ligands. Despite this physiological heterogeneity, these receptors share some primary sequence homology and are predicted by modeling to share a common tertiary structure. 
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